Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
3
×
boston blog main
boston top stories
clinical trials
life sciences
national blog main
national top stories
san francisco blog main
3
×
san francisco top stories
biotech
new york blog main
new york top stories
sanofi
alder biopharmaceuticals
boulder/denver blog main
boulder/denver top stories
calcitonin gene-related peptide
cancer
cancer drugs
cholesterol
chronic migraine
cobimetinib
data
david rind
deals
detroit blog main
detroit top stories
eli lilly
episodic migraine
eptinezumab
erenumab
fda
food and drug administration
fremanezumab
galcanezumab
inclisiran
indiana blog main
indiana top stories
institute for clinical and economic review
investing
What
drug
medicines
3
×
aces
amgen
announced
approval
big
cancer
candidates
ceo
cholesterol
class
despite
developed
family
fda
flexible
gets
hardest
head
hit
hottest
hunters
inclisiran
ipo
key
lowering
meant
medco
medicine
migraine
nasdaq
new
nod
open
pain
passed
preventive
pricing
proteins
Language
unset
Current search:
medicines
×
amgen
×
" san francisco blog main "
×
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com
5 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines
